Fig. 1

IgM titers and MMN patient serum-derived IgM binding to SCs and iPSC-MNs. (A) Correlation between IgM anti-GM1 and IgM anti-GM2 titers as determined via ELISA. (B) Sera from 98 MMN patient sera were screened for IgM binding to SCs using flow cytometry. IgM binding is depicted as fold-change (FC) compared to the mean IgM binding of 6 healthy control sera tested in the same assay on the y-axis. IgM binding to iPSC-MNs incubated with MMN sera using microscopy. IgM binding is expressed as FC similarly as in (A). (C) Stratification of MMN patients by IgM anti-ganglioside antibody status determined with ELISA reveals higher IgM binding to SCs in GM2 + versus GM1+/GM2- and -/- patients (Kruskal-Wallis, post-hoc Dunn’s multiple comparisons test). (D) Stratification of MMN patients by IgM anti-ganglioside antibody status indicates higher IgM binding to iPSC-MNs in GM1 + versus GM1- patients. Kruskal-Wallis, post-hoc Dunn’s multiple comparisons test. **** p < 0.0001; *** p < 0.001; FC: fold change; ns: non-significant